{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:26:03Z","timestamp":1785295563286,"version":"3.55.0"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In patients with relapsed\/refractory Burkitt lymphoma (r\/r BL), overall survival (OS) is poor, and effective therapies and evidence for the best therapy are lacking. The monoclonal antibody blinatumomab may represent a novel option. However, only limited data on the use of blinatumomab in r\/r BL are so far available. This multi-center, retrospective case series investigated nine patients with r\/r BL treated with blinatumomab. The safety of blinatumomab was assessed with respect to frequency and severity of adverse effects (AEs) infections, cytokine release syndrome (CRS) and neurotoxicity. Progression-free survival (PFS), OS and overall response rate (ORR) were analyzed to assess efficacy. No AEs &gt; grade 2 occurred, and AEs were generally treatable and fully reversible. The best response to blinatumomab was complete remission in 3\/9 patients and partial remission in 2\/9, whilst 4\/9 presented with progressive disease. Median PFS and OS were 2 and 6 months, respectively, ranging from 5 days to 32 months and 11 days to 32 months, respectively. Blinatumomab treatment was a successful bridging treatment to stem cell transplantation in 3\/9 patients. The response to blinatumomab varied widely, and only one patient survived longer term, but activity in patients with r\/r BL was evident in some patients, with its use being safe, warranting its prospective investigation.<\/jats:p>","DOI":"10.3390\/cancers15010044","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T02:31:11Z","timestamp":1671676271000},"page":"44","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Blinatumomab in Relapsed\/Refractory Burkitt Lymphoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Jeanne","family":"Bohler","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University Hospital Inselspital and University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, University Hospital Inselspital and University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Stadelmann","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-7747","authenticated-orcid":false,"given":"Michael","family":"Medinger","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Zander","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kantonsspital, 6000 Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Inselspital and University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"ref_1","unstructured":"Chamuleau, M.E.D., Stenner, F., Chitu, D., Novak, U., Minnema, M., Visser, O., Stevens, W., Zenz, T., van Imhoff, G., and Wu, K.L. (2022, January 9\u201312). R-CODOX-M\/R-IVAC Versus DA-EPOCH-R in Patients with Newly Diagnosed High-Risk Burkitt Lymphoma: First Results of a Multi-Center Randomized HOVON\/SAKK Trial. Proceedings of the EHA Congress Vienna AAL, Vienna, Austria."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","article-title":"Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens","volume":"97","author":"Oosten","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3816\/CLM.2009.n.060","article-title":"Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens","volume":"9","author":"Kelly","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1080\/10428194.2020.1747068","article-title":"Burkitt lymphoma: Bridging the gap between advances in molecular biology and therapy","volume":"61","author":"Zayac","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","article-title":"Adult Burkitt\u2019s and Burkitt-like non-Hodgkin\u2019s lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European Group for Blood and Marrow Transplantation","volume":"14","author":"Sweetenham","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-020-0898-8","article-title":"Burkitt and Burkitt-Like Lymphomas: A Systematic Review","volume":"22","author":"Saleh","year":"2020","journal-title":"Cur. Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"879983","DOI":"10.3389\/fimmu.2022.879983","article-title":"Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: A historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/BLCTT.S223894","article-title":"Evaluating Blinatumomab for the Treatment of Relapsed\/Refractory ALL: Design, Development, and Place in Therapy","volume":"10","author":"Sigmund","year":"2020","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy, and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma: A systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2011.08877.x","article-title":"Burkitt lymphoma in adults","volume":"156","author":"Linch","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_16","first-page":"67","article-title":"Blinatumomab Significantly Enhanced Cytotoxicity and T-Cell Cytokine Secretion Against Burkitt Lymphoma (BL) and Primary Mediastinal B-Cell Lymphoma (PMBL)","volume":"182","author":"Awasthi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/01.HS9.0000565624.37983.33","article-title":"Treatment of R\/R Burkitt lymphoma with blinatumomab is feasible and induced a long lasting complete remission","volume":"3","author":"Duell","year":"2019","journal-title":"HemaSphere"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A.G., Balch, C.M., Haller, D.G., and Morrow, M. (2002). Lymphoid Neoplasms. AJCC Cancer Staging Manual, Springer New York. [6th ed.].","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research","volume":"1","author":"Jaffe","year":"2009","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00277-017-3044-4","article-title":"In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: A single-center retrospective study","volume":"96","author":"Cremer","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00277-020-04221-0","article-title":"Concepts in immuno-oncology: Tackling B cell malignancies with CD19-directed bispecific T cell engager therapies","volume":"99","author":"Viardot","year":"2020","journal-title":"Ann. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:47:13Z","timestamp":1760147233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010044"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010044","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]}}}